Digital Therapeutics (DTx) for Disease Management

DTx for Healthcare

Digital therapeutics (DTx) is a rapidly growing field in the healthcare industry, providing new and innovative ways to treat and manage diseases and disorders.

DTx deliver medical interventions directly to patients using evidence-based, clinically validated software to treat or manage a broad spectrum of diseases and disorders. DTx can be delivered through a range of platforms depending on the target patient population, therapeutic area, and intended user experience. The DTx may be used alone or in conjunction with pharmaceutical therapies to improve patient outcomes, increase patient engagement, and potentially reduce healthcare costs.

Common delivery methods include mobile apps on smartphones and tablets, which offer portability and real-time interaction, and web-based applications accessible via browsers for broad device compatibility. Wearables and smartwatches enable passive monitoring and biofeedback, while virtual or augmented reality platforms provide immersive experiences for conditions like Post-Traumatic Stress Disorder (PTSD) or chronic pain. Some DTx are delivered via desktop software in clinical settings or through smart TVs and set-top boxes for populations with limited mobile access. Additionally, connected medical devices like insulin pumps or CPAP machines can integrate DTx for real-time management, and serious games or gaming consoles are used to engage users, particularly children, in therapeutic activities such as cognitive training or motor skill rehabilitation.

This is an exciting field which promises to accelerate health advancements. The FDA’s Digital Health Center of Excellence (DHCoE) provides regulatory advice and support for digital health technologies but does not itself review or approve marketing applications. Instead, the review of digital therapeutics applications is conducted by the relevant divisions within the FDA’s Center for Devices and Radiological Health (CDRH).

Over the past five years, the U.S. Food and Drug Administration has cleared or approved more than 35 digital therapeutics across various therapeutic categories.

Our History in Digital Health Innovation:

At Innovenn, we have been working in the digital health space in 2014 and have grown as experts in the development of digital health solutions which are regulated as Software as A Medical Device (SaMD). Our team can assist with the design, development, validation, regulatory strategy and serial submissions globally.

DTx Advantages

One of the key advantages of DTx is the ability to deliver targeted and personalized treatment to patients. Real-time tracking of symptoms and medication adherence can be made possible through a DTx app, making it easier for healthcare providers to monitor and adjust treatment plans as needed. Additionally, DTx can provide patients with educational and self-management feedback resources, empowering them to better understand and manage their condition.

DTx not only enhance patient outcomes but also offer opportunities to lower healthcare expenses. A study by the Journal of Medical Internet Research found that DTx can lead to a reduction in healthcare costs and an improvement in patient outcomes for conditions such as diabetes, hypertension, and heart failure¹. The use of DTx can also reduce the need for in-person visits to healthcare providers, making healthcare more accessible to patients in remote or underserved areas.

What are the regulatory considerations when developing DTx?

DTx products are held to the same standards of evidence and regulatory oversight as traditional medical treatments. The claims made by the developer (or manufacturer) must be approved by a regulatory or market authorization body unless the product is considered under enforcement discretion.

Evidence is needed to validate the accuracy and reproducibility of data collection, data driven interventions, and clinical mechanisms of action. These SaMD products must also adhere to current International and U.S. regulations including but not limited to ISO 13485, and 21 CFR 820).

In addition, DTx benefit from early user input and a rigorous validation program to validate the safety and efficacy of the DTx across potential use scenarios and with various users ensuring the highest possible usability as demonstrated through the conduct of Human Factors Testing.

Further, due to the sensitive nature of personal health information (PHI) which may be collected or shared via the DTx, patient privacy and data security considerations to enable protection of the patient’s data are vital. Design inputs and development considerations must consider methods for adherence to Privacy and Security guidances and regulations such as Health Insurance Portability and Accountability Act (HIPPA) and General Data Production Regulation (DGPF).

At Innovenn, we believe that designing in usability, privacy, security, scalability, data hosting, governance, ongoing risk analyses and mitigation efforts from the very early stages of design input through the complete product lifecycle are paramount.

What We Do

Innovenn breaks down the complexities of digital therapeutic app development and regulatory compliance by providing expertise in:

Device Description:

Collaboration with clients to clearly define app functionalities, ensuring effective acknowledgement of patient needs while complying with regulatory standards. This includes outlining user interaction workflows and key features in the Device Description.

Software Classification:

Help manufacturers determine their DTx software classification. Key deliverables for software development are dependent on the regulatory classification of the devices as well as the software safety classification.

Risk Management:

Develop a comprehensive risk management plan that identifies potential risks across software’s lifecycle. A thorough analysis of user safety, data privacy risks, and software performance, is done to prioritize mitigation strategies to safeguard against adverse events or operational failures.

Clinical Data (Validation):

Collaborate with clinical teams to gather and analyze clinical validation data, ensuring the DTx ’s effectiveness as a treatment. This data is essential for regulatory submission, demonstrating that apps meet safety and efficacy standards.

Labeling:

Develop clear and compliant user labeling and instructions for use, aligning with regulatory guidance to enable patients and healthcare providers safe and effective use of the platform.

Post-Market Surveillance Plans (Governance):

Develop a governance framework for post-market surveillance, setting up systems to monitor the software’s performance and patient outcomes after launch. This includes establishing reporting mechanisms for adverse events and real-time risk management.

Cybersecurity:

Lead efforts to define a cybersecurity risk management program, including identification of threats, mitigations, monitoring plans, and processes for updates to protect against new risks.

Regulatory 510(k) Submission & Design History File Documentation:

Drive the preparation of premarket submissions, including 510(k) submissions, ensuring the necessary technical documentation, including the device description, software details, risk management plan, and clinical data, are properly compiled and presented to the FDA. Innovenn also collaborates on creation of the Design History File (DHF), ensuring full compliance with relevant standards.

Global Regulatory Compliance:

Support DTx development by navigating various regulatory standards dependent on regions. In the U.S., this includes FDA regulations, HIPAA policies for data privacy, and HITECH for Health Information Technology. In Europe, DTx must comply with the EU Medical Device Regulation (MDR).

FAQs

What is the difference between DTx and traditional medications?

DTx refers to the use of software and technology to prevent, manage, and treat diseases and disorders. They may add to an existing treatment plan that could include traditional medications (prescription drugs and over-the-counter medications), devices, or provide standalone intervention.

How do DTx help with disease management?

DTx can provide targeted and personalized treatment to patients, improve patient outcomes, increase patient engagement, and reduce healthcare costs. Some examples of DTx currently on the market include mobile apps for diabetes management, digital programs for mental health treatment, and remote monitoring devices for heart failure management.

What are some of the challenges with implementing DTx?

Some of the challenges with implementing DTx include ensuring regulatory compliance, data privacy and security, and ensuring that the technology is user-friendly and easy for patients to use. The most important considerations for implementing health technologies are the need to carefully define the problem requiring a solution, understand the unmet needs of the population, and to design a solution that will make a difference in the patients’ lives and will encourage patient engagement.

Why Choose Innovenn for Digital Therapeutics (DTx) for Disease Management?

Choosing Innovenn for your DTx needs provides access to a depth of experience in design controls, software development, Human Factors Engineering, user experience, regulatory, privacy, and security who can support the development of health changing solutions. With an understanding of the importance of getting products to market as efficiently as possible, Innovenn always keeps patient needs in the center of development decisions.

To learn more about Innovenn’s Digital Therapeutics (DTx) for Disease Management services, contact us to discuss your specific needs.

Contact an Expert

Reference

Dang, A., Arora, D., & Rane, P. (2020, May 31). Role of Digital Therapeutics and the changing future of Healthcare. Journal of family medicine and primary care. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380804/

Where healthcare innovation intersects with improved patient outcomes

Contact Innovenn

6410 Enterprise Lane
Suite 230
Madison, WI 53719

608-203-9748

info@innovenn.com

Stay Informed

Sign Me Up